5:00 AM
 | 
Nov 14, 2018
 |  BC Extra  |  Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly identify effective treatments for newly diagnosed and recurrent glioblastoma. Dosing will begin early next year.

GBM AGILE will evaluate multiple agents across biomarker-defined subgroups, seamlessly moving compounds that clear the Phase II efficacy threshold into Phase III within the same protocol. GCAR President...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >